We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Prime Medicine, Inc. ( (PRME) ) has released its Q3 earnings. Here is a breakdown of the information Prime Medicine, Inc. presented to its ...

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Prime Medicine, Inc. (PRME – Research ... by a $55M upfront payment from a strategic partnership with Bristol Myers Squibb. This ...

Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling ...

Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by ...

Prime Gaming’s lineup of free games for November has been announced with Amazon curating a list of 24 different titles that’ll be given away this month. The free Prime Gaming games for ...

By Michael Erman (Reuters) -Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

(RTTNews) - Bristol-Myers Squibb Co. (BMY) announced earnings for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.211 billion ...